PX-21440-A BLACK PLASTISOL PX-21440-B BLACK PLASTISOL PX-21440-C BLACK PLASTISOL

Geon(TM) FM207 ROSE SCENT FOAM PLASTISOL FB606 White Foam Plastisol FB607 Black Sponge Plastisol

Geon(TM) DM750 RASPBERRY PLASTISOL Geon(TM) DM750 CUCUMBER PLASTISOL Geon(TM) DM750 BLACK CHERRY PLASTISOL

PX-8595-A BLUE POOL FILTER PLASTISOL BARN RED PLASTISOL IVORY PLASTISOL

PLASTISOL PX-21433-A WHITE PLASTISOL PX-21433-B YELLOW PLASTISOL

PX-20482-B YELLOW HOT DIP PLASTISOL PX-20482-A GRAY HOT DIP PLASTISOL PX-20482-C BLUE HOT DIP PLASTISOL

PX-15421-E ORANGE HOT DIP PLASTISOL PX-15421-F YELLOW HOT DIP PLASTISOL 9211-21 DARK GREEN THERMOSET PLASTISOL

MB3087A Plastisol (lower odor M3334) MB3087B Plastisol (lower odor M3334) MB3087C Plastisol (lower odor M3334)

19500-011 RED PLASTISOL PX-21459-B HOT DIP PLASTISOL PX-13494-F ORANGE PLASTISOL

D is t. ) R P M P P G K W R F U L A V Y G C P IF F F M C H X L H U N E M N F O E E C L K R A S C L A S H C E G R A A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of February 5, 2021 Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 83% Median: 76% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of February 5, 2021 85 87 86 86 81 81 59 92 88 81 79 79 79 76 76 75 73 67 67 64 60 7 A vi en t P P G K W R R P M F U L A V Y G C P IF F F M C U N V R H X L E M N B N R E C L C E A S H F O E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of February 5, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 27 Avient reflects 2021 estimated EBITDA of $510M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 9.5 21.1 13.2 13.2 12.0 12.0 9.7 25.2 23.1 14.7 13.5 12.9 11.0 11.0 11.0 10.2 9.6 9.3 9.3 9.1 8.6 8.3 A vi en t K W R A V Y R P M G C P P P G F U L A L B E C L H X L IF F F M C G R A B N R F O E A S H C E S C L U N V R E M N H U N K R A Median: 11.0xMedian: 12.6x SUMMARY: WHY INVEST IN AVIENT?